Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Exp Physiol. 2012 Jun;97(6):699-709. doi: 10.1113/expphysiol.2011.063461. Epub 2012 Jan 27.
In this study, we evaluated whether the activation of endogenous angiotensin-converting enzyme 2 (ACE2) would improve the cardiovascular autonomic dysfunction of diabetic rats. Ten days after induction of type 1 diabetes (streptozotocin, 50 mg kg(-1) i.v.), the rats were treated orally with 1-[(2-dimethylamino)ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one (XNT), a newly discovered ACE2 activator (1 mg kg(-1) day(-1)), or saline (equivalent volume) for 30 days. Autonomic cardiovascular parameters were evaluated in conscious animals, and an isolated heart preparation was used to analyse cardiac function. Diabetes induced a significant decrease in the baroreflex bradycardia sensitivity, as well as in the chemoreflex chronotropic response and parasympathetic tone. The XNT treatment improved these parameters by ≈ 76% [0.82 ± 0.09 versus 1.44 ± 0.17 Ratio between changes in pulse interval and changes in mean arterial pressure (ΔPI/ΔmmHg)], ∼85% (-57 ± 9 versus -105 ± 10 beats min(-1)) and ≈ 205% (22 ± 2 versus 66 ± 12 beats min(-1)), respectively. Also, XNT administration enhanced the bradycardia induced by the chemoreflex activation by v 74% in non-diabetic animals (-98 ± 16 versus -170 ± 9 Δbeats min(-1)). No significant changes were observed in the mean arterial pressure, baroreflex tachycardia sensitivity, chemoreflex pressor response and sympathetic tone among any of the groups. Furthermore, chronic XNT treatment ameliorated the cardiac function of diabetic animals. However, the coronary vasoconstriction observed in diabetic rats was unchanged by ACE2 activation. These findings indicate that XNT protects against the autonomic and cardiac dysfunction induced by diabetes. Thus, our results provide evidence for the viability and effectiveness of oral administration of an ACE2 activator for the treatment of the cardiovascular autonomic dysfunction caused by diabetes.
在这项研究中,我们评估了内源性血管紧张素转换酶 2(ACE2)的激活是否会改善糖尿病大鼠的心血管自主神经功能障碍。在诱导 1 型糖尿病(链脲佐菌素,50mg/kg 静脉注射)后 10 天,大鼠口服 1-[(2-二甲氨基)乙基氨基]-4-(羟甲基)-7-[(4-甲基苯基)磺酰氧基]-9H-呫吨-9-酮(XNT),一种新发现的 ACE2 激活剂(1mg/kg/day),或生理盐水(等体积),治疗 30 天。在清醒动物中评估自主心血管参数,并使用离体心脏制备物分析心脏功能。糖尿病导致压力感受性反射性心动过缓敏感性、化学感受性变时反应和副交感神经张力显著下降。XNT 治疗使这些参数分别改善了约 76%[0.82±0.09 与 1.44±0.17 之间的脉搏间隔变化与平均动脉压变化的比值(ΔPI/ΔmmHg)]、约 85%(-57±9 与-105±10 次/min)和约 205%(22±2 与 66±12 次/min)。此外,XNT 给药增强了非糖尿病动物化学感受性激活引起的心动过缓,增加了 74%[-98±16 与-170±9 Δ 次/min]。各组的平均动脉压、压力感受性反射性心动过速敏感性、化学感受性升压反应和交感神经张力均无显著变化。此外,慢性 XNT 治疗改善了糖尿病动物的心脏功能。然而,ACE2 激活并未改变糖尿病大鼠的冠状动脉收缩。这些发现表明,XNT 可预防糖尿病引起的自主神经和心脏功能障碍。因此,我们的结果为口服 ACE2 激活剂治疗糖尿病引起的心血管自主神经功能障碍的可行性和有效性提供了证据。